| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rotary Magnetic field can be generated by a spinning magnet or magnets. Or it can be implemented with 2 or more coils, power with a phase shift between them (90 deg for 2 coil implementation) (60deg for 3 coil implementation) Targets affected are mostly the same as for Magnet fields Main differences - may enhance the EPR effect allowing targeting of drugs to cancer cells - acts as wireless stirrer, especially on magnetic particles(inducing eddy currents in water media) - research for use in nano surgery, and mechanical destruction of cancer cells - continue to highlight ability to raise ROS in cancer cell and lower ROS in normal cells - RMF may be responsible for Ca2+ distribution to pass across the plasma membrane(differental affected for cancer and normal cells) Pathways: - induce ROS production in cancer cells, while decreasing ROS in normal cells. Ca2+ is critical and the Ca2+ balance is increased in cancer cells while decreased in normal cells (example for wound healing) - ROS↑ related: MMP↓(ΔΨm), Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx, - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓, - inhibit Growth/Metastases : TumMeta↓, TumCG↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, RhoA↓, NF-κB↓, TGF-β↓, ERK↓ - cause Cell cycle arrest : TumCCA↑, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓, - Others: PI3K↓, AKT↓, Wnt↓, AMPK, ERK↓, JNK, - Synergies: < Others(review target notes), Neuroprotective, Cognitive, - Selectivity: Cancer Cells vs Normal Cells Rotating Magnetic Fields
Time-Scale Flag: TSF = P / R / G P: 0–30 min (physical / electron / radical effects) R: 30 min–3 hr (redox signaling & stress response) G: >3 hr (gene-regulatory adaptation)MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure. |
| Source: |
| Type: |
| Mitochondrial Complex II - Succinate Dehydrogenase Complex Abbreviation: Complex II, CII, SDH Components: SDHA, SDHB, SDHC, SDHD Type: Mitochondrial electron transport chain complex / TCA cycle enzyme Function: Mitochondrial Complex II, also known as succinate dehydrogenase (SDH), links the tricarboxylic acid (TCA) cycle with the electron transport chain. It oxidizes succinate to fumarate while transferring electrons through FAD and iron-sulfur centers to ubiquinone. Complex II contributes to mitochondrial respiration, cellular metabolism, reactive oxygen species regulation, and control of intracellular succinate levels. Cancer: ↕ Context-dependent. Loss or inactivation of SDH/Complex II can promote tumorigenesis through accumulation of the oncometabolite succinate, inhibition of α-ketoglutarate-dependent dioxygenases, epigenetic dysregulation, and stabilization of pseudohypoxic signaling. SDH-deficient tumors include subsets of paraganglioma, pheochromocytoma, gastrointestinal stromal tumor, and renal cell carcinoma. Conversely, increased Complex II activity can support oxidative phosphorylation and tumor-cell metabolism in some cancers. |
| 188- | MFrot, | MF, | Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells |
| - | in-vitro, | GBM, | GBM115 | - | in-vitro, | GBM, | DIPG |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:192 Target#:1633 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid